| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Other income (expense), net | 7,476,601 | -22,263,921 | -11,750,575 | -13,003,969 |
| Income (loss) before income taxes | 15,690,347 | -564,214 | -10,652,765 | -9,519,026 |
| Income tax expense | 1,987,940 | 5,320,501 | 239,175 | 1,517,203 |
| Net income (loss) attributable to common shareholders | 13,702,407 | -5,884,715 | -10,891,940 | -11,036,229 |
| Basic net income (loss) per share attributable to common shareholders | 0.01 | -0.01 | -0.01 | -0.01 |
| Basic weighted average common stock outstanding | 1,071,897,174 | 1,068,363,108 | 1,068,273,108 | 1,068,273,108 |
| Diluted net income (loss) per share attributable to common shareholders | 0.01 | -0.01 | -0.01 | -0.01 |
| Diluted weighted average common stock outstanding | 1,141,536,381 | 1,068,363,108 | 1,068,273,108 | 1,068,273,108 |
ELITE PHARMACEUTICALS INC NV (ELTP)
ELITE PHARMACEUTICALS INC NV (ELTP)